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Abstract
Background We aimed to evaluate the effectiveness of
PAE in weaning of catheter and relieving obstructive uri-
nary symptoms in patients with acute urinary retention
(AUR) due to benign prostatic hypertrophy (BPH) and
failed trial without catheter (TWOC).
Materials and Methods In this prospective study approved
by the institutional review board, a signed informed con-
sent was obtained. Eighteen consecutive patients with AUR
due to BPH and failed TWOC were recruited. Nineteen
consecutive patients with BPH but without AUR were
recruited as a control. Patients with CTA evidence of
arterial occlusion or significant stenosis along the prostate
artery access path were excluded. PAE was performed
using microspheres (100–300 lm diameter). Outcome
assessment included successful weaning of catheter in
2 weeks, procedure-related complications, change of
symptomatology and urodynamic findings at 1 month as
compared to baseline, percent non-perfused prostate vol-
ume, and prostate volume reduction on MRI at 2 weeks.
Results Two patients in the study group and four in the
control group were excluded due to arterial pathology.
Embolization of bilateral prostate arteries was achieved in
all patients in both the groups (100%). There was no
complication. The catheter was successfully weaned in
87.5% (14/16) of patients within 14 days in the treatment
group. There was no significant difference in patient
demographics, prostate characteristics, and all outcome
assessment parameters between both the groups.
Conclusions PAE was probably safe and effective in
weaning of catheter and relieving obstructive urinary
symptoms in patients due to BPH, with treatment outcomes
comparable to those without AUR.
Keywords Benign prostatic hypertrophy  Acute
retention of urine  Prostate artery  Embolization
Introduction
The standard initial management of acute urinary retention
(AUR) due to benign prostatic hypertrophy (BPH) is
immediate bladder catheterization followed by trial without
catheterization (TWOC) after 3 days of catheterization [1].
Alpha-blockers are playing an important role in managing
patients with symptomatic BPH. In patients presenting with
a first episode of spontaneous AUR related to BPH, alpha-
blocker such as Alfuzosin XL 10 mg per oral daily sig-
nificantly increases the success rate of TWOC [2, 3].
Patients with BPH-related AUR and failed TWOC while on
alpha-blocker are usually treated with transurethral resec-
tion of prostate (TURP), which is effective in relieving the
complete obstruction at the bladder outlet. However, TURP
is associated with a number of complications such as blood
loss requiring blood transfusion (0.4–7%), urinary incon-
tinence (30–40%), retrograde ejaculation (65–80%),
impotence (5%), infection, urethral stricture, and need for
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surgical retreatment for lower urinary tract symptoms
(3–14.5%) [4–7]. Others include infection and urethral
stricture. Prostate artery embolization (PAE) has been
introduced as a treatment for patients with symptomatic
BPH [8–12]. Although PAE is generally less invasive than
TURP, the effectiveness of PAE in relieving the obstruc-
tive effect of BPH in patients with AUR and failed TWOC
is unclear. We aim to evaluate the effectiveness of PAE in
the weaning of catheter and relieving obstructive urinary




This was a prospective study that was conducted in
accordance to the Declaration of Helsinki and interna-
tional standards of Good Clinical Practice, and approved
by the institutional review board. A signed informed
consent was obtained from all patients. It was hypothe-
sized that for patients with a Foley catheter placed for
AUR due to BPH and failed TWOC despite alpha-
blocker therapy, PAE is effective in the weaning of
catheter and relieving the obstructive urinary symptoms
to a degree comparable to that in patients with symp-
tomatic BPH without AUR. From June 2015 to March
2016, 37 consecutive patients who had fulfilled all the
eligibility criteria were recruited into the study (Table 1).
Eighteen patients with AUR due to BPH and failed
TWOC despite having on alpha-blocker (Alfuzosin XL
10 mg oral daily) were allocated into a study group.
These patients were on a waiting list for TURP and had
an indwelling Foley’s catheter placed for 21–107 days
(average 69.5 ± 32.8 days) before PAE. Nineteen
patients with symptomatic BPH but without AUR, being
on alpha-blocker (Alfuzosin XL 10 mg oral daily), with
International Prostate Symptom Score (IPSS) C 15,
quality of life score 3 or above, and urine peak flow rate
less than 15 mL/s, were allocated into a control group.
The patients were then assessed with CTA for evidence
of vascular occlusion or severe stenosis along the rele-
vant vascular access path. Two patients in the study
group were excluded due to CTA evidence of complete
occlusion of one of the internal iliac arteries, or severe
stenosis at the origin of one of the inferior vesicle
arteries. Four patients in the control group were excluded
because of severe stenosis of one of the inferior vesical
arteries. Sixteen patients in the study group and 15
patients in the control group received PAE (Table 2).
Study Endpoints
The primary endpoint was successful weaning of Foley
catheter within 2 weeks of PAE. The secondary endpoints
were safety outcome, clinical outcome, and urodynamic
outcome at 1 month, and imaging outcome at 2 weeks.
The Treatment
PAE was performed with a standardized technique for all
patients in both groups. This was an in-patient procedure.
Pre-medication included the following: oral Voltaren
SR100 mg (Diclofenac Sodium, Novartis Pharmaceuticals,
Basel, Switzerland) once daily; famotidine 20 mg (Merck
Sharp and Dohme. NSW, Australia) twice daily given for
2 days before the procedure, and in the morning of the
procedure; Dulcolax rectal suppository 10 mg (Boehringer
Ingelheim Pharma, Deutschland) given in the night before
the procedure; and intravenous Ciprofloxacin 400 mg
(Bayer HealthCare Ltd, Hong Kong) given within 1 h
before the procedure. Patients were fasted for 6 h. For
patients in the control group, a Foley catheter was placed
for the procedure. In all patients, the Foley balloon was
prepared before the procedure using 1 mL of contrast
(Omnipaque 350, Amersham Health, Cork, Ireland) diluted
to 10 mL (35 mgI/L) with water for injection and placed at
the vesico-ureteric junction; this was used as a reference
under fluoroscopy to localize the prostate. A single oper-
ator, who had 23 years of experience in endovascular
procedures but no experience in PAE, performed all the
procedures. The procedures were performed under local
anesthesia using 5 mL of 1% lignocaine without parenteral
sedation or analgesia. The right femoral artery was punc-
tured using a Minipuncture Introducer Set (Cook Medical,
Bloomington, USA). The arterial supply to the prostate was
mapped with bilateral internal iliac angiography using tube
rotation at ipsilateral 35–50 and cranial-caudal angula-
tion at 10. Microcatheters (Merit Maestro 2.4F, Merit
Medical Systems Inc., Utah, USA) were used for selective
catheterization of the bilateral prostate arteries (Fig. 1).
Cone-beam CT angiography or rotational angiography was
performed to confirm catheter position and prostate stain-
ing when there was suspicion about potential non-prostate
embolization. Embolization was performed using tris-acryl
microspheres (Embosphere microspheres, Merit Medical)
of diameter 100–300 lm, with 2 mL particle suspended in
a mixture of 5 mL water and 10 mL Omnipaque 350,
which was slowly delivered under fluoroscopic guidance
until there was flow stasis in the prostate arteries (Fig. 2).
Post-procedure medication included oral Voltaren
SR100 mg once daily and famotidine 20 mg twice daily
for 10 days, and oral ciprofloxacin 500 mg twice daily for
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7 days. Alpha-blockers were discontinued 1 month after
PAE.
Outcome Assessment
The procedure time and fluoroscopy time as indicated in
the angiographic equipment were captured. TWOC was
performed on day 3 and 14 in the study group and on day 3
in the control group in the initial protocol, because the
authors initially thought that it would take at least 3 days
for the prostate to shrink and the obstructive effects to be
relieved after embolization. Subsequently, it was observed
that successful TWOC could be achieved on day 1. The
protocol was therefore changed to have TWOC performed
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
1. Willing to sign an informed consent 1. Active urinary tract infection, or
2. Age between 50 and 80 years old, and 2. Biopsy proven prostate or bladder cancer, or any cancer other than basal or
squamous cell skin cancer, or
3. Known history of symptoms of lower urinary tract
obstruction attributable to benign prostatic hypertrophy, and
3. Bladder atonia, neurogenic bladder disorder or other neurological disorder
that is impacting bladder function, or
4. Prostate size C50 g on ultrasound, and 4. Urethral stricture, bladder neck contracture, sphincter abnormalities, urinary
obstruction due to causes other than BPH, or other potentially confounding
bladder or urethral disease or condition, or
5. Serum PSA level\4 ng/mL or C4 with cancer excluded by
biopsy, unless biopsy is refused by the patient
5. Previous surgery or transurethral resection of prostate, needle ablation,
balloon dilation, stent implantation, or any other invasive treatment to the
prostate, or
For patients in the study group 6. Patient unable to receive MRI imaging, or
1. Presented with acute urinary retention, and 7. Baseline serum creatinine level[1.8 mg/dl, or
2. Managed with transurethral placement of Foley catheter in
urinary bladder, and
8. Known upper tract renal disease, or
3. Put on Alfuzosin XL 10 mg oral daily, and 9. Active prostatitis, or
4. Failed trial without catheter 10. Previous rectal surgery other than hemorrhoidectomy, or history of rectal
disease, or
For patients in the control group 11. History of pelvic irradiation or radical pelvic surgery, or known major iliac
arterial occlusive disease1. Quality of life score C3, and
2. Urine flow rate\15 mL/s at a total bladder volume
C150 mL, and
3. Prostate size of at least 50 grams as measured on
ultrasound, and
4. On Alfuzosin XL 10 mg oral daily
Table 2 Patient demographics
and baseline characteristics
Baseline characteristics Study group (n = 16) Control group (n = 15) P value
Age (year) 66 (60.3, 70.3) 66 (60, 72) 0.953
Prostate volume (mL) 77 (55.1, 94.3) 65.6 (41.6, 81.9) 0.165
Serum PSA level (lg/L) 14 (7.5, 18.4) 8.2 (5.3, 17.7) 0.206
IPSS 21 (13.5, 25.3) 19 (16, 22) 0.579
QOL score 6 (5, 6) 4 (4, 5) 0.004
Urinary peak flow rate (mL/s) 2.5 (0, 5) 5 (4, 8) 0.005
IIEF 7.5 (4, 18.5) 9 (1, 23) 0.937
Results were provided as median and (inter-quartile range)
The results of IPSS, QOL score, urinary peak flow rate, and IIEF in the study group were those before the
onset of acute urinary retention
PSA Prostate specific antigen, IPSS International Prostate Symptom Score, QOL Quality of life, IIEF
International Index of Erectile Function
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on day 1, 3, 7 in the study group and on day 1 after PAE.
Regarding safety outcome, peri-PAE complications within
1 month were prospectively captured, including any
puncture site complications, arterial dissection, intra-pro-
cedural or post-procedural pain in perineal, retropubic or
urethral region; any other post-embolization syndrome
such as nausea, vomiting, fever, or small amount of blood
in urine or stool [6]; any signs and symptoms of prostatic or
pelvic infection, infarction of the bladder, rectum, or gen-
itals; or any event that had led to prolonged hospitalization
or hospital readmission. For this purpose, patients were
observed during the procedure and during the following
3 days of hospitalization and symptoms were prospectively
captured, symptoms on day 2 and 3 were prospectively
Fig. 1 Selective arteriogram of the right prostate artery was
performed at ipsilateral oblique 50 and caudal tilt 10 before
embolization. Prostate vasculature was outlined. The prostate location
was hinted with a Foley balloon that was pointed out with arrows (A).
Selective arteriograms after embolization showed no contrast staining
in the prostate (B)
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captured with telephone contact if the patient was dis-
charged from hospital, and patients were interviewed at
1 month. For pain assessment, patients were asked to rate
their pain severity from 0 (sensation of no pain) to 10 (the
worst pain imaginable). Regarding imaging outcome,
contrast-enhanced MRI was performed at baseline and at
two weeks. Percent prostatic volume reduction from
baseline and the percentage of non-perfused volume on
contrast-enhanced MRI were estimated. The extent of non-
perfused volume was used as an indicator to assess the
status of prostate embolization. Regarding clinical out-
come, the patients’ clinical symptoms were assessed with
IPSS and Quality of Life score (QOL) at one month and
compared with those at baseline. Regarding urodynamic
outcome, urine peak flow rate, and post-void residual urine
volume at 1 month were assessed and compared with those
at baseline.
Imaging Protocols
CTA was performed with a 64-slice multi-detector CT
(General Electrics). The power settings were 100–120 kV
and 200–300 mA; matrix, 512 9 512 pixels; field of view
360 9 360 mm; voxel size, 0.7 9 0.7 9 1.25 mm; colli-
mation, 16 9 1.25 mm; and pitch, 1.3. Power injection
settings were 100 mL of iodinated contrast (Omnipaque
350), injection rate 4 mL/s, and bolus triggering in the
abdominal aorta. Threshold level for acquisition was
200 HU. The delay is usually 16–20 s. A 30-mL saline
flush before and after contrast injection at the same rate as
the contrast injection is performed in every patient.
Sublingual vasodilator (0.5 mg nitroglycerin, Quilaban,
Quı´mica Laboratorial Analı´tica Lda) was given before
image acquisition to help identify small arteries. The mean
acquisition time was 12 s for a scanning range of 30 cm.
MRI was acquired using a Philips Achieva Tx 3T
scanner using a sense cardiac coil (receive) and a body coil
(transmit). T2W multi-shot TSE pulse sequences were
acquired in the sagittal, coronal, and axial planes. After the
baseline scan, 0.2 mL/kg gadoteric acid (0.5 mmL/mL;
DOTAREM, Guerbet, France) was injected intravenously
by hand (2 mL/s) with 20 mL 0.9% saline flush. Starting
from the time of injection, images were acquired at 6.9 s
intervals with a total of 13 acquisitions. Post-contrast fat
saturated e-THRIVE sequences were then performed in the
axial and coronal planes. MRI data were processed with
computer programs for volumetric assessment.
Statistical Analysis
Continuous data were presented as median and inter-
quartile range. Patient proportions in treatment outcome
analysis were presented as percentages. Comparison of
continuous variables between the two patient groups was
performed with Mann–Whitney U test. Comparison of
patient proportions between the two patient groups was
performed with Fisher’s exact test. Difference between the
two patient groups was considered not significant when
P C 0.05.
Results
PAE with selective catheterization of bilateral prostate
arteries was successfully performed in all 31 patients. All
31 patients who received PAE had completed imaging
assessment at 2 weeks and clinical, urodynamics, and
safety assessments at 1 month. The serum prostate-specific
antigen (PSA) level was high at baseline; it was 14 lg/L
[Median, inter-quartile range (IQR) 7.5, 18.4] and 8.2 lg/L
(Median, IQR 5.3, 17.7) in the study group and control
group, respectively (Table 2). There was no histology or
MRI evidence of prostatic carcinoma in all 31 patients. The
procedure time and fluoroscopy time in the study group
were 116.5 min (Median, IQR 97.3, 144) and 34 min
(Median, IQR 25.8, 43.8), respectively, and those in the
control group were 116 min (Median, IQR 87, 162) and
31 min (Median, IQR 17, 36), respectively. There was no
significant difference in the procedure time or fluoroscopy
time between the two groups (Table 3). In the initial nine
patients of the study group, TWOC was successful on day 3
in three patients and successful on day 14 in five patients;
TWOC was failed in 1 patient. In the other seven patients of
the study group, TWOC was successful on day 1 in two
patients, day 3 in three patients, and day 7 in one patient;
TWOCwas failed in one patient. Altogether, 14 patients out
of 16 in the study group had successfully weaned off
Foley’s catheter within 2 weeks after PAE; the success rate
was 87.5%. In the control group, TWOC was successful on
day 3 in all the initial six patients, and on day 1 in all the
other nine patients (Table 4). The two patients who failed
TWOC after PAE underwent TURP, the symptoms of lower
urinary tract obstruction due to BPH subsided afterward.
There was no peri-procedural complications, no post-
embolization pain of severity[2 out of 10, or any other
adverse events. The results of other outcome assessments
bFig. 2 Selective arteriogram of the left prostate artery was performed
at ipsilateral oblique 50 and caudal tilt 10 before embolization.
Prostate vasculature was outlined between the urinary bladder on the
left and the rectum on the right (A, B). The Foley balloon as pointed
out with arrowheads located within the bladder lumen that was
almost completely collapsed (A). The intravesical portion of the
prostate as pointed out with arrows showed prostate vasculature
inside (A, B). Selective arteriogram after embolization showed no
contrast staining in the prostate (C)
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are shown in Table 3. The serum PSA level was substan-
tially reduced at 1 month after PAE; it was 5.2 lg/L
(Median, IQR 3.6, 7.4) and 6.6 lg/L (Median, IQR 3.4,
10.2) in the study group and control group, respectively.
Prostate volume reduction C10% at 2 weeks occurred in
57.1% of patients in the study group and 53.3% of patients
in the control group. Non-perfused prostate volumes were
79% (Median, IQR 73, 81) in the study group and 80%
(Median, IQR 74, 83) in the control group. Reduction in
IPSS C50% at 1 month occurred in ten patients (71.4%) of
the study group and ten patients (66.7%) in the control
group. Increase in QOL C3 at 1 month occurred in nine
patients (64.3%) of the study group and eight patients
(53.3%) of the control group. Increase in urine peak flow
rate C5 mL/s at 1 month occurred in seven patients (50%)
in the treatment group and eight patients (53.3%) in the
control group. There was no significant difference between
the two groups in all the outcome parameters.
Discussion
This study showed that the success rate of PAE in relieving
complete urinary obstruction in patients with AUR due to
BPH is high (87.5%). There was no complication or sexual
dysfunction after PAE. The treatment outcome as assessed
Table 3 Treatment outcome
Outcome parameters Study group (n = 16) Control group (n = 15) P value
Weaned off Foley’s catheter 14 (87.5%) 15 (100%) 0.484
Total procedure time (min) 116.5 (97.3, 144) 116 (87, 162) 0.913
Fluoroscopy time (min) 34 (25.8, 43.8) 31 (17, 36) 0.247
Prostate volume at 2 weeks (mL) 65.6 (47.5, 90.4) 62.1 (34.8, 70.6) 0.239
Prostate volume reduction at 2 weeks (%) 12.4 (7.9, 17.4) 12.6 (4.3, 20.4) 0.663
Percent non-perfused volume at 2 weeks 79 (73, 81) 80 (74, 83) 0.389
Serum PSA level 1 month (lg/L) 5.2 (3.6, 7.4) 6.6 (3.4, 10.2) 0.678
Serum PSA reduction (%) 49 (34.9, 65.2) 37.1 (4.7, 58.4) 0.138
IPSS at 1 month 5.5 (5, 11.3) 7 (2, 11) 0.38
IPSS reduction C25% at 1 month 13 (92.9%) 14 (93.3%) [0.999
IPSS reduction C50% at 1 month 10 (71.4%) 10 (66.7%) [0.999
QOL at 1 months 2 (1, 3) 1 (0, 2) 0.223
QOL improved C1 at 1 month 14 (100%) 14 (93.3%) [0.999
QOL improved C3 at 1 month 9 (64.3%) 8 (53.3%) 0.825
Peak flow rate at 1 month 8 (5, 10.1) 12 (9, 15) 0.051
Peak flow rate increase C2.5 mL/s at 1 month 11 (78.6%) 11 (73.3%) [0.999
Peak flow rate increase C5 mL/s at 1 month 7 (50%) 8 (53.3%) [0.999
IIEF at 1 months 4.5 (1.8, 19.8) 9 (3, 22) 0.605
IIEF reduction value 0 (0, 0) 0 (0, 0) 0.526
Continuous data of the results were provided as median and (inter-quartile range)
PSA Prostate specific antigen, IPSS International Prostate Symptom Score, QOL Quality of life score, IIEF International Index of Erectile
Function
Table 4 Schedule and outcome
of trial without catheter
(TWOC)
Timing of TWOC (day) Study group (N = 16) Control group (N = 15)
N attempted N succeeded N attempted N succeeded
1 (7) (2) (9) (9)
3 9 ? (5) 3 ? (3) 6 6
7 (2) (1)
14 6 5
Total N succeeded within 2 weeks 14 15
Number in brackets = N of patients in the second batch
Note that the total number of attempts of TWOC in the study group was greater than 16 since some of the
attempts were unsuccessful and therefore repeated
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by imaging, clinical, and urodynamic parameters had
shown significant improvement as compared to baseline,
and no difference between the groups with or without acute
urinary retention. These findings have confirmed the find-
ing of a previous study by Carnevale et al. [9], in which 11
patients with acute urinary retention caused by BPH treated
with PAE resulted in successful catheter removal and
symptomatic improvement in 91%. Patients can be treated
safely with PAE, resulting in overall clinical improvement
in lower urinary tract symptoms as assessed by QOL and
urodynamic data.
These results implied that that PAE could be an effec-
tive and safe alternative to TURP for patients with AUR
due to BPH, who fail to wean off urinary catheter despite
having on alpha-blocker, are not amenable to general or
regional anesthesia, or not willing to expose themselves to
the risk of complications associated with TURP. Failure of
PAE does not preclude the patient from receiving TURP.
The techniques of CTA, pelvic arteriogram, Foley
balloon localization, and prostate artery catheterization
used in this study have been reported before [9]. The use
of a Foley balloon in PAE procedures for patients without
AUR may not be justified anymore because it would
induce patient distress and it carries a risk of urinary tract
infection and urethral injury, given that the need for using
a Foley balloon for anatomical localization of the prostate
is diminished with the use of cone-beam CT or rotational
angiography. Diclofenac was started 2 days before the
procedure to reduce ischemic and inflammatory pain
during the procedure. In the studies by Pisco et al.,
Naproxen 1000 mg twice daily was given for 2 days
before PAE, and there was totally no pain during the
procedure in 79% of patients [8, 10]. This may account
for the absence of post-PAE pain of severity[2 out of 10
in all patients in our study, when post-PAE pain and other
post-embolization syndrome were not uncommon in other
studies. Microspheres of diameter 100–300 lm were used
in this study, while microspheres of 300–500 lm were
used in other studies [9, 13]. Although smaller sized
microspheres could possibly be more effective in reaching
the terminal branches of the prostate artery and causing
more extensive ischemic necrosis of the prostate, they
could be more risky in inadvertent embolization of non-
target pelvic organs. Bladder wall necrosis presenting
with severe intra-procedural pain had occurred after PAE
in which polyvinyl alcohol particles of size 100–200 lm
(Cook Medical) were used [10]. In a small-scale non-
randomized comparative study with 15 patients in each
arm, Embosphere microspheres of size 100–300 lm and
size 300–500 lm were compared for use in PAE for BPH.
Although there was no significant difference in functional
and imaging outcomes between the two groups, there was
a greater incidence of adverse events in the group of
smaller particles [14]. In the current study, in which tris-
acryl microspheres of size 100 to 300 lm were used,
embolization-related complications did not occur, sug-
gesting that it may be safe to use smaller sized micro-
spheres. Regarding the determination of the optimal size
of microspheres for PAE, further studies involving larger
numbers of patients, longer durations of follow-up, clin-
ical outcome, and imaging of the extent of necrosis would
be necessary.
The high serum PSA level in both groups was probably
due to BPH, as well as an element of prostatitis. The higher
PSA level in the study group relative to the control group
was likely due to a greater degree of prostatitis induced by
the long-term indwelling intravesical catheter, which is not
uncommon among this group of patients. Marked reduction
in the PSA level after PAE was probably another indicator
of the therapeutic effect of PAE on BPH, as well as reso-
lution of prostatitis following the removal of the intraves-
ical catheter.
The patient number of this study was relatively small,
although the endpoints of procedure safety and effective-
ness in weaning off the intravesical catheter within
2 weeks were clearly demonstrated. The follow-up period
of this study was relatively short. Although substantial
favorable changes in symptomatology, urodynamics, and
serological parameters had already been shown at 1 month
as compared to baseline, further changes at a later stage
were not evaluated. A future report of longer term follow-
up might be interesting. The study design of comparison to
a control group allowed evaluation of the treatment effect
of PAE in patients with AUR, with reference to those
without AUR. It might be valuable to further evaluate the
role of PAE in AUR in a randomized control trial of larger
scale, in comparison with TURP, to study the complica-
tions, short-term and long-term outcomes of symptoma-
tology and urodynamic changes, and the need and outcome
of a repeat PAE.
In conclusion, PAE was probably safe and effective in
weaning of catheter and relieving obstructive urinary
symptoms in patients with AUR due to BPH, with treat-
ment outcomes comparable to those without AUR. Further
studies with longer follow-up and larger patient cohorts are
needed.
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